| 1 |
Jones TC. A call to restructure the drug development process: government over-regulation and non-innovative late stage (Phase III) clinical trials are major obstacles to advances in health care. Sci Eng Ethics 2005;11:575-87. [PMID: 16279756 DOI: 10.1007/s11948-005-0027-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 2 |
Horton DB, Gerhard T, Davidow A, Strom BL. Impact of the black triangle label on prescribing of new drugs in the United Kingdom: lessons for the United States at a time of deregulation. Pharmacoepidemiol Drug Saf 2017;26:1307-13. [PMID: 28857309 DOI: 10.1002/pds.4304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 3 |
Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med. 2006;119:719-727. [PMID: 16945603 DOI: 10.1016/j.amjmed.2005.11.006] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 4 |
Buyse M, Molenberghs G, Paoletti X, Oba K, Alonso A, Van der Elst W, Burzykowski T. Statistical evaluation of surrogate endpoints with examples from cancer clinical trials: Statistical evaluation of surrogate endpoints. Biom J 2016;58:104-32. [DOI: 10.1002/bimj.201400049] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 5 |
Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia 2002;43:983-92. [PMID: 12199723 DOI: 10.1046/j.1528-1157.2002.01702.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 6 |
Molenberghs G, Burzykowski T, Alonso A, Assam P, Tilahun A, Buyse M. A unified framework for the evaluation of surrogate endpoints in mental-health clinical trials. Stat Methods Med Res 2010;19:205-36. [PMID: 19608602 DOI: 10.1177/0962280209105015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 7 |
Alonso A, Molenberghs G. Surrogate end points: hopes and perils. Expert Review of Pharmacoeconomics & Outcomes Research 2014;8:255-9. [DOI: 10.1586/14737167.8.3.255] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 8 |
Pryseley A, Tilahun A, Alonso A, Molenberghs G. An information-theoretic approach to surrogate-marker evaluation with failure time endpoints. Lifetime Data Anal 2011;17:195-214. [DOI: 10.1007/s10985-010-9185-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 9 |
Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, Mismetti P, Bertoletti L. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res 2017;118:19-32. [PMID: 27521835 DOI: 10.1016/j.phrs.2016.08.017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 39] [Article Influence: 8.7] [Reference Citation Analysis]
|
| 10 |
Lancia P, Aurich B, Ha P, Maisin A, Baudouin V, Jacqz-Aigrain E. Adverse Events under Tacrolimus and Cyclosporine in the First 3 Years Post-Renal Transplantation in Children. Clin Drug Investig 2018;38:157-71. [PMID: 29236209 DOI: 10.1007/s40261-017-0594-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
Key C, Layton D, Shakir SAW. Results of a postal survey of the reasons for non-response by doctors in a Prescription Event Monitoring study of drug safety. Pharmacoepidem Drug Safe 2002;11:143-8. [DOI: 10.1002/pds.690] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 12 |
Williams D, Kelly A, Feely J. Association between SSRIs and upper gastrointestinal bleeding. Coprescription of antiulcer drugs with SSRIs is fairly common. BMJ. 2000;320:1405; author reply 1406. [PMID: 10858058 DOI: 10.1136/bmj.320.7246.1405] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 13 |
Jones TC. Call for a new approach to the process of clinical trials and drug registration. BMJ 2001;322:920-3. [PMID: 11302912 DOI: 10.1136/bmj.322.7291.920] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
|
